EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY-NC 4.0

CD20 × CD3 Bispecific Antibodies in B‐NHL: A Review of Translational Science, Pharmacokinetics, Pharmacodynamics, and Dose Strategy in Clinical Research

Min Zhu iD, Xiaowen Guan iD, Samit Ganguly iD, Erik Welf iD, John D Davis iD

Clinical and Translational Science · 2025-06 · 18 (6)

DOI: 10.1111/cts.70250 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Clinical and Translational Science, online erschienen am 05.06.2025. Verfasst von Min Zhu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA. Hauptthemen laut MEDLINE: Antibodies, Bispecific, Antigens, CD20, CD3 Complex, Lymphoma, B-Cell. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 107 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Despite advancements in treatment for B‐cell non‐Hodgkin lymphoma (B‐NHL) in recent decades, many patients still relapse or are refractory to treatment, which represents a high unmet medical need. Novel CD20 × CD3 T‐cell–engaging bispecific antibodies (bsAbs) have created a new paradigm for the treatment of B‐NHL. Pivotal studies of four CD20 × CD3 bsAbs, mosunetuzumab, glofitamab, epcoritamab, and odronextamab, as monotherapy, have demonstrated robust responses with generally manageable safety profiles in patients with relapsed or refractory follicular lymphoma and diffuse large B‐cell lymphoma after ≥ 2 lines of systemic therapy. These agents have presented unique challenges (e.g., cytokine release syndrome [CRS]), which have required different strategies to overcome. This review provides a comprehensive overview of the clinical development of these four CD20 × CD3 bsAbs that have been investigated for the treatment of B‐NHL, with a specific focus on translational assessments to select starting doses in first‐in‐human studies, management of CRS, application of modeling and simulation approaches to aid dose escalation and optimization/selection, and strategies used in the design of phase I–III clinical trials. By highlighting learnings and experiences from these four bsAbs assessed, which have not been summarized collectively elsewhere, we aim to promote more efficient study design for novel bsAbs in B‐NHL in the future.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, BispecificAntigens, CD20CD3 ComplexLymphoma, B-CellAntineoplastic Agents, ImmunologicalHumansTranslational Research, BiomedicalDose-Response Relationship, DrugCytokine Release Syndrome

Stichwörter der Autor:innen

clinical trialsdosedrug developmentexposure responsehematologymodel‐based drug developmentmonoclonal antibodiesoncologypharmacodynamicspharmacokinetics

Substanzen

Antibodies, BispecificAntigens, CD20CD3 ComplexAntineoplastic Agents, Immunological

Autor:innen und Institutionen

  • Regeneron Pharmaceuticals, Inc., Tarrytown, New York, USA.
  • Orion Corporation, Espoo, Finland.

ORCID-Profile: Min Zhu, Xiaowen Guan, Samit Ganguly, Erik Welf, John D Davis

Zitieren

APA

Zhu, M., Guan, X., Ganguly, S., Welf, E., & Davis, J. D. (2025). CD20 × CD3 Bispecific Antibodies in B‐NHL: A Review of Translational Science, Pharmacokinetics, Pharmacodynamics, and Dose Strategy in Clinical Research. Clinical and Translational Science, 18(6). https://doi.org/10.1111/cts.70250

Vancouver

Zhu M, Guan X, Ganguly S, Welf E, Davis JD. CD20 × CD3 Bispecific Antibodies in B‐NHL: A Review of Translational Science, Pharmacokinetics, Pharmacodynamics, and Dose Strategy in Clinical Research. Clinical and Translational Science. 2025;18(6). doi:10.1111/cts.70250

BibTeX
@article{Zhu2025,
  author = {Zhu, Min and Guan, Xiaowen and Ganguly, Samit and Welf, Erik and Davis, John D},
  title = {CD20 × CD3 Bispecific Antibodies in B‐NHL: A Review of Translational Science, Pharmacokinetics, Pharmacodynamics, and Dose Strategy in Clinical Research},
  journal = {Clinical and Translational Science},
  year = {2025},
  volume = {18},
  number = {6},
  doi = {10.1111/cts.70250}
}
Kostenlos starten →